Clinical Validation of Digital PCR–Based ctDNA Detection for Risk Stratification in Residual Triple-Negative Breast Cancer: TRICIA Trial Results
These findings suggest that ctDNA testing using ddPCR assays in an academic hospital-based context can reliably identify a very low-risk group of non-pCR TNBC patients.
Authors
- Oluwadara Elebute
- Josiane Lafleur (ORCID: https://orcid.org/0000-0003-4459-8801)
- Suzan McNamara
- Terry L. Ng (ORCID: https://orcid.org/0000-0001-6128-3137)
- Anna Klemantovich
- Mark Basik (ORCID: https://orcid.org/0000-0002-2633-5410)
- Luca Cavallone (ORCID: https://orcid.org/0000-0002-1627-2145)
- Talia Roseshter (ORCID: https://orcid.org/0000-0002-7410-4887)
- Cathy Lan
- Juliet Guay
- Kathryn Bozek (ORCID: https://orcid.org/0000-0002-6659-8119)
- Manuella Pelmus
- Rodney J. Ouellette (ORCID: https://orcid.org/0000-0002-2281-2769)
- Muriel Brackstone
- Adriana Aguilar-Mahecha
- Sarah Jenna
- Jean-Francois Boileau
- Rossanna Pezo
Institutions
- Ottawa Hospital (CA)
- London Health Sciences Centre (CA)
- Jewish General Hospital (CA)
- Atlantic Cancer Research Institute (CA)
- IGNIS Innovation (Canada) (CA)
- Intelligent Machines (Sweden) (SE)
- Sunnybrook Hospital (CA)
- McGill University (CA)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-02-09
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-2234
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00